HEART TEST LABORATORIES INC (HSCS)
US42254E1047 - Common Stock
HSCS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 196 industry peers in the Health Care Equipment & Supplies industry. While HSCS seems to be doing ok healthwise, there are quite some concerns on its profitability. HSCS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year HSCS has reported negative net income.
In the past year HSCS has reported a negative cash flow from operations.
1.2 Ratios
The Return On Assets of HSCS (-59.18%) is worse than 73.98% of its industry peers.
HSCS has a worse Return On Equity (-74.04%) than 61.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -59.18% | ||
| ROE | -74.04% | ||
| ROIC | N/A |
ROA(3y)-183.68%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HSCS has a Gross Margin of 67.31%. This is in the better half of the industry: HSCS outperforms 74.49% of its industry peers.
The Profit Margin and Operating Margin are not available for HSCS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.31% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
HSCS does not have a ROIC to compare to the WACC, probably because it is not profitable.
HSCS has more shares outstanding than it did 1 year ago.
HSCS has a better debt/assets ratio than last year.
2.2 Solvency
HSCS has an Altman-Z score of -7.59. This is a bad value and indicates that HSCS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of HSCS (-7.59) is worse than 72.96% of its industry peers.
HSCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.59 |
ROIC/WACCN/A
WACC9.29%
2.3 Liquidity
HSCS has a Current Ratio of 5.09. This indicates that HSCS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.09, HSCS is in the better half of the industry, outperforming 69.90% of the companies in the same industry.
HSCS has a Quick Ratio of 4.70. This indicates that HSCS is financially healthy and has no problem in meeting its short term obligations.
HSCS has a better Quick ratio (4.70) than 74.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.09 | ||
| Quick Ratio | 4.7 |
3. Growth
3.1 Past
HSCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.70%, which is quite impressive.
Looking at the last year, HSCS shows a decrease in Revenue. The Revenue has decreased by 0.00% in the last year.
Measured over the past years, HSCS shows a very negative growth in Revenue. The Revenue has been decreasing by -44.97% on average per year.
EPS 1Y (TTM)38.7%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q81.25%
Revenue 1Y (TTM)0%
Revenue growth 3Y-44.97%
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
HSCS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.29% yearly.
Based on estimates for the next years, HSCS will show a very strong growth in Revenue. The Revenue will grow by 1211.75% on average per year.
EPS Next Y74.19%
EPS Next 2Y36.55%
EPS Next 3Y25.99%
EPS Next 5Y25.29%
Revenue Next Year2272%
Revenue Next 2Y2656.81%
Revenue Next 3Y1563.1%
Revenue Next 5Y1211.75%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for HSCS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HSCS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
HSCS's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.55%
EPS Next 3Y25.99%
5. Dividend
5.1 Amount
No dividends for HSCS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HEART TEST LABORATORIES INC
NASDAQ:HSCS (4/19/2024, 7:00:02 PM)
After market: 0.0985 0 (-1.6%)0.1001
-0.01 (-7.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap6.56M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -59.18% | ||
| ROE | -74.04% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.31% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.09 | ||
| Quick Ratio | 4.7 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)38.7%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y74.19%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)0%
Revenue growth 3Y-44.97%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y